Market News / Story
Argenx falls after ending late-stage trial for Sjögren's disease therapy
Seeking Alpha ·
Seeking Alpha reports: Argenx ADRs fell more than 14% in the premarket on Thursday after the Dutch biotech announced the discontinuation of a late-stage trial for an injectable version of its blockbuster therapy Vyvgart targeted at an autoimmune condition called Sjögren's disease. The Phase 3 UNITY study enrolled adults with moderate-to-severe Sjögren's disease to test the subcutaneous version of the drug, also known as efgartigimod alfa, designed using Halozyme's Enhanze drug delivery…